Nektar extends surge after promising eczema drug data
Nektar Therapeutics NKTR.O shares up 14.9% to $64.33, over two-month high on Weds, adding to big gain in prior session after its eczema drug showed promise
NKTR shares surged 51% on Tues after co earlier in the day said rezpegaldesleukin showed year-long benefit
After the bell Tues, NKTR commenced $300 mln offering consisting of stock and pre-funded warrants in part to fund Phase 3 trials for rezpegaldesleukin
Jefferies, TD Cowen and Piper Sandler joint bookrunners
BTIG on Tues said after the data NKTR remains one of its 1H26 top picks and hiked its PT from $118 to $151
7 of 8 analysts rate stock "strong buy" or "buy", 1 "hold"; median PT $115, per LSEG data
With the move on Weds, NKTR shares up more than six-fold over the past 12 months
Related Articles
Strategy Defies DAT Sell-Off, Doubles Down Amid Leverage Woes
MicroStrategy acquired over 1,000 additional Bitcoins last week, with Michael Saylor stating the company will purchase Bitcoin every quarter moving forward.
Silver Faces Sixth Consecutive Year of Supply Deficit, How Much Upside Is Left in 2026?
TradingKey - According to the 2026 Silver Market Outlook recently released by the Silver Institute, the current robust performance of the silver market remains supported by solid fundamentals. The report indicates that the global silver market is expected to face a structural supply-demand imbalance
Retail Trading Hub Robinhood Sinks Again, Slumping Over 7% After Hours, Signaling Lack of Interest in Crypto?
TradingKey - Robinhood (HOOD) reported a 34% decline in fourth-quarter net profit to $605 million, with total revenue of $1.28 billion missing Wall Street expectations.
After $20B Debt Sale, Google’s Rare 100-Year Bond Sparks Scrutiny: Has AI Drained the Tech Giant’s Coffers?
TradingKey - According to a Financial Times report, Google parent Alphabet (GOOG)(GOOGL) is planning to issue bonds denominated in British pounds and Swiss francs, which may include the first 100-year GBP bond of this century.
U.S. January Nonfarm Payrolls Preview: Likely to Beat Expectations, but with Limited Impact on US Stocks
TradingKey - Against the backdrop of the U.S. economy demonstrating robust resilience and the coordinated easing of monetary and fiscal policies, the nonfarm payrolls data are likely to beat the market consensus expectations.
